Home Executive-Insights CCO BVI Medical Appoints Andrew Ch...

BVI Medical Appoints Andrew Chang as Chief Commercial Officer to Lead Global Growth

CCO

Business Honor
07 May, 2025

Veteran ophthalmic leader to drive sales, marketing, and product growth worldwide.

Waltham, Massachusetts-based global ophthalmic device firm BVI Medical has appointed Andrew Chang as its new Chief Commercial Officer. Chang will be responsible for worldwide sales, marketing, and commercial activities. Chang will report to Shervin Korangy, President and CEO of BVI Medical.

The new appointment is particularly timely for the company, as it readies itself for future growth and launches a number of new products. The company, in fact, only last month closed a financing round worth $1 billion, a significant benchmark that will facilitate the company's strategic initiatives. Among these are its expansion of intraocular lens (IOL) manufacturing within Europe and commercializing its flagship monofocal lenses, Serenity and Serenity Toric.

Chang has over 20 years of ophthalmology and medical device experience. Prior to joining BVI, he was in senior roles at Carl Zeiss Meditec, including President of the U.S. business and worldwide head of ophthalmic device sales. He also held senior positions at Bausch + Lomb, OptiMedica, and ISTA Pharmaceuticals.

Chang was Senior Vice President and General Manager of U.S. Surgical at Bausch + Lomb. His broad experience encompasses managing sales strategies, bringing new products to market, and managing international teams.

BVI Medical was confident that Chang's leadership will play a key role as the company enters its next development stage. With its robust pipeline of products and plans for global expansion, the company says that his experience will aid in driving its commercial success and market presence.

Andrew Chang’s appointment highlights BVI’s focus on building a high-performing leadership team to drive innovation and growth in the eye care industry.